Condition: Peanut Allergy · Sponsor: Moonlight Therapeutics, Inc.
The goal of this open-label, single escalating dose study in 3 sequential groups: adults, adolescents, and children with peanut allergy is to assess the safety of MOON101. The main question it aims to answer is: 1. the incidence and frequency of all treatment emergent adverse events (TEAEs) from baseline through study exit. 2. to determine the highest tolerated dose for each participant, as defined by the highest MOON101 dose level administered which did not cause a dose-limiting symptom (DLS). The study will compare MOON101 and placebo. All participants will receive both active MOON101 (peanut allergen) and placebo (no peanut allergen).
This description comes directly from the study's public registry record.
Michelle C Widmann · 9196001819 · trials@moonlighttx.com
Samir Patel, PhD · 404-348-8294 · trials@moonlighttx.com
Always discuss trial participation with your own doctor first.
| Arkansas Children's Research Institute | Little Rock, Arkansas, United States | Recruiting |
| Children's Healthcare of Atlanta | Atlanta, Georgia, United States | Recruiting |
| Dr. Vince Clinical Research | Overland Park, Kansas, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| University of North Carolina at Chapel Hill | Chapel Hill, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07580898